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Abstract 
Background: Hypertension is one of the strongest risk factors for stroke in the general population, while systolic 
blood pressure has been shown to independently increase the risk of stroke in type 1 diabetes. The aim of this study 
was to elucidate the association between different blood pressure variables and risk of stroke in type 1 diabetes, and 
to explore potential nonlinearity of this relationship.
Methods: We included 4105 individuals with type 1 diabetes without stroke at baseline, participating in the nation‑
wide Finnish Diabetic Nephropathy Study. Mean age at baseline was 37.4 ± 11.9 years, median duration of diabe‑
tes 20.9 (interquartile range 11.5–30.4) years, and 52% were men. Office systolic blood pressure (SBP) and diastolic 
blood pressure (DBP) were measured. Based on these pulse pressure (PP) and mean arterial pressure (MAP) were 
calculated. Strokes were classified based on medical and autopsy records, as well as neuroimaging. Cox proportional 
hazard models were performed to study how the different blood pressure variables affected the risk of stroke and its 
subtypes.
Results: During median follow‑up time of 11.9 (9.21–13.9) years, 202 (5%) individuals suffered an incident stroke; 
145 (72%) were ischemic and 57 (28%) hemorrhagic. SBP, DBP, PP, and MAP all independently increased the risk 
of any stroke. SBP, PP, and MAP increased the risk of ischemic stroke, while SBP, DBP, and MAP increased the risk of 
hemorrhagic stroke. SBP was strongly associated with stroke with a hazard ratio of 1.20 (1.11–1.29)/10 mmHg. When 
variables were modeled using restricted cubic splines, the risk of stroke increased linearly for SBP, MAP, and PP, and 
non‑linearly for DBP.
Conclusions: The different blood pressure variables are all independently associated with increased risk of stroke in 
individuals with type 1 diabetes. The risk of stroke, ischemic stroke, and hemorrhagic stroke increases linearly at blood 
pressure levels less than the current recommended treatment guidelines.
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Background
Hypertension is one of the strongest risk factors for 
stroke in the general population, and the risk of stroke 
increases linearly when blood pressure levels exceed 
115/75  mmHg [1]. Blood pressure variables, such as 
systolic blood pressure (SBP), diastolic blood pressure 
(DBP), and mean arterial pressure (MAP), are all asso-
ciated with an increased risk of stroke [2], and lowering 
of the blood pressure with any antihypertensive agent 
reduces the risk with as much as 30% [3]. However, while 
lowering blood pressure levels linearly decreases the 
risk of stroke in the general population, there has been 
evidence of a J-shaped phenomenon in individuals with 
diabetes [4, 5]. Zhao et  al. showed that a systolic blood 
pressure < 110  mmHg, as well as > 160  mmHg, signifi-
cantly increases the risk of stroke in individuals with dia-
betes. This J-shaped association is significant specifically 
in younger individuals under the age of 60.
Blood pressure, SBP especially, has been identified as 
an important risk factor for stroke also in type 1 diabe-
tes [6, 7]. We have also previously shown that systolic 
blood pressure, among longer diabetes duration, diabetic 
micro- and macrovascular complications, poor glycemic 
control, and a history of smoking, is independently asso-
ciated with an increased risk of stroke in type 1 diabetes 
[8]. How the other blood pressure variables DBP, MAP 
and PP are associated with the risk of stroke and its sub-
types is still unclear in type 1 diabetes. Increased sodium 
intake, expressed as a higher urinary sodium excretion, 
leads to higher blood pressure, and to increased risk of 
cardiovascular disease, stroke included [9]. Paradoxically, 
in individuals with type 2 diabetes, lower 24-h urinary 
sodium (24-h Na) excretion increased the risk of all-cause 
and cardiovascular mortality [10]. The same was seen in 
individuals with type 1 diabetes even after adjusting for 
hypertension [11]. While higher sodium intake increases 
the cardiovascular risk in the general population, higher 
potassium consumption seems to have a protective influ-
ence on this risk [12]. It is not known how sodium and 
potassium excretion affect the risk of stroke in type 1 
diabetes, nor is it known how low blood pressure levels 
affect the risk of stroke in these individuals.
The aim of this study was to elucidate the impact of dif-
ferent blood pressure variables and levels on the risk of 
stroke and its subtypes ischemic stroke and hemorrhagic 
stroke in individuals with type 1 diabetes. Moreover, we 
wanted to determine the impact of urinary sodium and 
potassium excretion on the risk of stroke.
Methods
All participants were part of the Finnish Diabetic 
Nephropathy (FinnDiane) Study, a nationwide multi-
center study with the aim to uncover risk factors and 
mechanisms for micro- and macrovascular complications 
of type 1 diabetes. The study was launched in 1997, and 
patient recruitment is still ongoing. A detailed descrip-
tion of the research design and the population has previ-
ously been reported [13]. All adult individuals with type 
1 diabetes, attending the 77 participating study centers’ 
(Additional file  6: Appendix) diabetes and/or renal out-
patient clinics, were consecutively asked to participate 
in the study. The participants in the study underwent 
a clinical examination at a regular visit to the attend-
ing physician. Both the attending physician, as well as 
the participant, completed standardized questionnaires 
regarding the participant’s medical condition, medical 
history and medication, as well as smoking habits. In 
addition, blood samples were drawn, and overnight or 
24-h urine collections were performed. Follow-up infor-
mation is collected regularly from registries and review 
of medical files. For this study, we excluded participants 
without information on systolic blood pressure (151 par-
ticipants), diastolic blood pressure (two participants), 
and without information on antihypertensive medication 
(32 participants). Due to unclear information on stroke 
at baseline, a total of 15 individuals with stroke were 
excluded from the study. In addition, two participants 
were excluded due to subdural hemorrhages, one due 
to traumatic hemorrhage, one due to perinatal hemor-
rhage, and one due to hypertensive encephalopathy. This 
resulted in a total of 4105 individuals with type 1 diabe-
tes in the FinnDiane database without a stroke at baseline 
and with complete information on stroke during follow-
up available. The local ethics committee of each center 
approved the study protocol, and the study was carried 
out in accordance with the Declaration of Helsinki. Each 
participant signed a written informed consent.
Diabetes and renal status
We defined type 1 diabetes as diabetes diagnosis before 
40  years of age and insulin medication commenced 
within 1  year after diagnosis. The mean age at baseline 
was 37.4 ± (standard deviation) 11.9  years, the median 
duration of diabetes was 20.9 (interquartile range 11.5–
30.4) years, and 52% of the participants were men. Each 
participant collected timed urine samples for the meas-
urement of urinary albumin excretion rate (UAER). Dia-
betic nephropathy (DN) was defined as having a UAER 
of ≥ 200  µg/min or ≥ 300  mg/24  h or having end-stage 
renal disease (ESRD). ESRD was defined as ongoing 
dialysis treatment or kidney transplantation. Severe dia-
betic retinopathy (SDR) was defined as history of retinal 
photocoagulation. Coronary heart disease (CHD) was 
defined as a history of myocardial infarction or coronary 
artery revascularization, or treatment with long-acting 
nitroglycerin.
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Blood pressure, sodium, and potassium measurements
Blood pressure was measured by a trained nurse dur-
ing the exam visit twice in the sitting position with a 
10 min rest before the first measurement, and the mean 
values of these two measurements were calculated for 
both the systolic blood pressure (SBP) and the diastolic 
blood pressure (DBP). Pulse pressure (PP) was calcu-
lated as SBP–DBP. Mean arterial pressure (MAP) was 
calculated as DBP+ 1
/
3PP . Antihypertensive medication 
was defined as the use of any anti-hypertensive agent; 
angiotensin-converting-enzyme inhibitors, angiotensin 
receptor blockers, calcium channel blockers, β-blockers, 
diuretics, or other antihypertensive agents (mainly moxo-
nidine). Hypertension was defined as SBP > 140  mmHg 
and/or DBP > 90 mmHg. 24-h Na and 24-h urinary potas-
sium (24-h  K) excretion were measured from a 24-h 
urine collection. Sodium/potassium ratio (Na/K ratio) 
was defined as 24-h Na divided by 24-h  K. Information 
on sodium and potassium urinary excretion was available 
for 2402 (59%) individuals during follow-up.
Stroke
A detailed description of the identification and classi-
fication of the strokes has previously been described in 
detail [13]. For this study, we had additional follow-up 
data available until the end of 2012. Follow-up data was 
available in all participants. In short, individuals with an 
incident stroke were identified from the FinnDiane ques-
tionnaires, death certificates, and the National Care Reg-
ister of Health Care. Medical records from the attending 
hospitals, brain computed tomography and magnetic res-
onance images, as well as death certificates were ordered 
on these individuals. Based on these data, all the strokes 
were classified into ischemic or hemorrhagic stroke by 
two stroke neurologist (J.P and R.L), with the help from 
an experienced neuroradiologist when needed. Follow-
up time was calculated from the baseline visit until the 
last date the participants were known to be free of stroke, 
or until the date of the first stroke for those who suffered 
a stroke, resulting in 45,050 person-years of follow-up.
Statistical analyses
All variables included were tested for normal distribu-
tion by visual inspection. Parametric continuous vari-
ables were analyzed with Student’s t-test, and the results 
are presented as means with standard deviation. Non-
parametric variables were analyzed with Mann–Whitney 
U-test, the results are presented as medians with inter-
quartile range. The difference in categorical variables 
between groups was tested with the χ2-test. Cox pro-
portional hazard models were performed to study how 
SBP, DBP, MAP, and PP affected the risk of any stroke, 
ischemic stroke, and hemorrhagic stroke. The results 
are presented as hazard ratio (HR) with 95% confidence 
interval (CI). Blood pressure variables were included in 
different models because of collinearity, with only one 
blood pressure variable in each model. The multivari-
ate models were adjusted for the variables that statisti-
cally differed in the univariate analyses (Additional file 2: 
Table S2), which resulted in adjustments for sex, diabetes 
duration, waist circumference, DN, SDR,  HbA1c, LDL-
cholesterol, current or history of smoking, use of antihy-
pertensive medication, presence of CHD, and year of the 
FinnDiane study visit.
Since participant mortality due to other causes than 
stroke is a competing event to stroke, we performed com-
peting risk analyses to take this into account. We exam-
ined the association between SBP and stroke using the 
proportional subdistribution hazards regression model 
by Fine and Gray [14], with death as a competing event. 
The results are presented as subhazard ratio (SHR) with 
95% CI, and is defined as the hazard of a given cause in 
the presence of the competing event.
To assess the shapes of the association between the 
continuous variables SBP, DBP, MAP, and PP and the risk 
of stroke, we fitted unadjusted Cox proportional haz-
ard models with each variable included as a restricted 
cubic spline with three knots. The number of knots was 
selected based on the Akaike information criteria [15], 
and located at the 10th, 50th, and 90th percentiles, corre-
sponding to the values listed in Additional file 1: Table S1. 
The median values were used as the reference point in the 
analyses. HR was then estimated based on the restricted 
cubic spline models and used to create plots for graphi-
cal assessment of the relationships. We implemented the 
Wald test to determine whether the relationship between 
the blood pressure variables and stroke significantly devi-
ated from linearity. P < 0.05 was considered statistically 
significant. The restricted cubic spline analyses were 
performed with Harrell’s Regression Modelling Strate-
gies (rms) package [16], while the competing risk analy-
ses were performed with the ‘cmprsk’ package [17] in the 
R software [18]. All other analyses were performed with 
the SPSS Statistical software 25.0 (IBM Corporation, 
Armonk, NY).
Results
In total, 202 (5%) individuals with type 1 diabetes suf-
fered an incident stroke during follow-up. Of these, 145 
(72%) individuals suffered an ischemic stroke, and 57 
(28%) a hemorrhagic stroke. The blood pressure vari-
ables, antihypertensive medication, and urinary sodium 
and potassium excretion of those with an incident stroke 
compared to those without stroke during follow-up are 
shown in Table 1. All measures of blood pressure levels 
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were higher in those with an incident stroke. The use of 
any type of antihypertensive medication was far more 
common in those with a stroke, and no differences in 
sodium or potassium excretion were seen. The other 
characteristics of those with an incident stroke compared 
to those without are shown in Additional file 2: Table S2. 
In short, those with a stroke were older, had a longer 
duration of diabetes and more cardiovascular complica-
tions. In addition, DN, SDR, and smoking were more fre-
quently occurring in those with an incident stroke. Those 
with stroke had higher total cholesterol, LDL-cholesterol, 
and triglycerides, as well as poorer glycemic control.
Cox proportional hazards models were performed to 
study the independent effect of blood pressure variables 
on the risk of stroke; the results are shown in Table  2. 
For any stroke, SBP, DBP, MAP, and PP all indepen-
dently increased the risk of stroke. For ischemic stroke, 
SBP, MAP, and PP independently increased the risk, 
while DBP was not significant in the model (Table 2). For 
hemorrhagic stroke, SBP, DBP, and MAP independently 
increased the risk, while PP was not significant (Table 2). 
When DBP, MAP, and PP, in turn, were included in the 
same model as SBP, SBP remained significant in the 
model for any stroke and ischemic stroke, while for hem-
orrhagic stroke, only MAP remained significant in the 
model (data not shown). Taking death into consideration 
as a competing event to stroke, the SHR for the different 
blood pressure variables did not significantly change for 
any type of stroke or ischemic stroke. For hemorrhagic 
stroke, DBP was no longer significant in the analyses 
(Table 2).
Cox proportional hazard models using restricted cubic 
splines were performed to see how the blood pressure 
variables affected the risk of stroke, without assuming 
linearity. Figure  1 shows the estimated HRs for stroke 
for variables SBP, DBP, MAP, and PP. A linear associa-
tion was found for SBP, MAP, and PP, and the increase in 
risk was linear across the entire range of blood pressure 
variable values (Fig. 1). For DBP, however, there was no 
increase in risk at values below 80 mmHg, after which the 
risk started to increase (Fig. 1). Comparable results were 
seen for the stroke subtypes ischemic stroke and hemor-
rhagic stroke (Additional file 3: Figure S1).
Similar Cox proportional hazards models as for the 
blood pressure variables were performed for 24-h Na, 
24-h K, and Na/K-ratio, and these variables did not 
Table 1 Clinical characteristics according to type of stroke during follow-up
Data are presented as mean ± standard deviation, median with interquartile range, or number of cases (%)
ACE inhibitor angiotensin‑converting‑enzyme inhibitor
*P < 0.05 compared to no stroke
Baseline data No stroke Any stroke Ischemic stroke Hemorrhagic stroke
n 3903 202 145 57
Men (%) 51 63* 63* 61
Age (years) 36.9 ± 11.8 45.8 ± 9.5* 46.6 ± 9.5* 44.4 ± 9.1*
Duration of diabetes (years) 20.0 (11.7–29.3) 31.0 (24.4–36.8)* 32.0 (25.4–37.0)* 28.6 (25.0–34.9)*
Age at stroke (years) – 52.2 ± 9.8 53.1 ± 10.0 49.9 ± 8.9
Blood pressure measurements
 Systolic blood pressure (mmHg) 133 ± 18 150 ± 23* 150 ± 23* 149 ± 23*
 Diastolic blood pressure (mmHg) 79 ± 10 83 ± 11* 83 ± 11* 83 ± 12*
 Pulse pressure (mmHg) 54 ± 16 67 ± 19* 68 ± 20* 66 ± 18*
 Mean arterial pressure (mmHg) 97 ± 11 105 ± 13 105 ± 13* 105 ± 14*
 Hypertensive (%) 32 66* 68* 60*
 24‑h urinary sodium excretion (mmol/l) 140 (101–185) 145 (98–192) 149 (98–202) 138 (96–161)
 24‑h urinary potassium excretion (mmol/l) 83 (62–105) 79 (59–104) 79 (56–104) 82 (61–103)
 Sodium/potassium ratio 1.74 (1.32–2.30) 1.76 (1.45–2.33) 1.81 (1.47–2.35) 1.67 (1.39–1.78)
Medication
 Antihypertensive medication (%) 36 78* 78* 77*
  ACE inhibitor (%) 24 45* 48* 38*
  Angiotensin receptor blocker (%) 5 12* 12* 11
  Calcium channel blocker (%) 11 33* 35* 27*
  β‑Blocker (%) 12 38* 38* 38*
  Diuretic (%) 11 36* 36* 38*
  Other (%) 1 2* 1 4*
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increase the risk of stroke and its subgroups in any of 
the models (data not shown). In the restricted cubic 
spline analysis for 24-h Na, 24-h  K, and Na/K-ratio, no 
increased risk of any stroke, ischemic stroke, or hemor-
rhagic stroke was seen for neither low nor high intake 
(Additional file 4: Figure S2 and Additional file 5: Figure 
S3).
Discussion
In this study, we show that all different blood pres-
sure variables, i.e., SBP, DBP, PP, and MAP, indepen-
dently increased the risk of stroke in individuals with 
type 1 diabetes. The same except for DBP was seen for 
ischemic stroke, while SBP, DBP and MAP independently 
increased the risk of hemorrhagic stroke. The effect of 
blood pressure variables on the risk of stroke and its sub-
types proved to be linear for SBP, MAP, and PP. Notably, 
no J-shaped association was observed for any blood pres-
sure variable or stroke subtype, neither was sodium or 
potassium excretion associated with an increased risk of 
stroke in this study.
Impact of different blood pressure variables on the risk 
of stroke
As in the general population [19, 20], SBP seems to be a 
very strong risk factor for stroke also in type 1 diabetes. 
SBP remained significant as a risk factor for total stroke 
and ischemic stroke when compared with the other vari-
ables in the Cox regression models. PP is the pulsatile 
variable of blood pressure and, as such, a marker for 
large artery stiffness. PP has been shown to increase the 
risk of stroke in the general population, and the associa-
tion seems to be linear [2]. The association of DBP and 
stroke is, however, less clear since this blood pressure 
variable does not increase with age, instead, it decreases 
[21], leading to a weaker association with stroke. This 
also explains the non-linear association with DBP and 
stroke in the restrictive cubic spline regression models. 
Rawshani et al. [7] also showed that the association with 
DBP and stroke is rather weak. MAP, on the other hand, 
is considered to be the perfusion pressure in organs in 
the body and is composed of both SBP and DBP [22]. 
The significant association reflects this for any stroke as 
well as for both subtypes in the present study. We are not 
aware of any previous studies on MAP and stroke in type 
1 diabetes.
Blood pressure levels and the risk of stroke
In individuals with type 2 diabetes, the risk of stroke 
increases after blood pressure exceeds 130/80  mmHg 
[23]. In our study, the risk of stroke starts to increase 
at similar DBP levels, while for SBP, linear increase is 
observed even earlier. In a recent study by Rawshani 
et al. [7], similar results were seen for SBP, although the 
risk started to increase for stroke at a slightly higher 
level compared to our study. The treatment recommen-
dation for blood pressure levels in diabetes is, despite 
these facts, higher; according to the American Diabetes 
Table 2 Blood pressure as a risk factor for any stroke, ischemic stroke, and hemorrhagic stroke
Data are presented as hazard ratio with 95% confidence interval, as well as subhazard ratio with 95% confidence interval. Model also included sex, waist 
circumference, diabetes duration, diabetic nephropathy,  HbA1c, LDL‑cholesterol, severe diabetic retinopathy, any smoking, antihypertensive medication, coronary 
heart disease, and year of the FinnDiane study visit. Blood pressure variables were included in separate models
SBP systolic blood pressure, DBP diastolic blood pressure, MAP mean arterial pressure, PP pulse pressure
Any stroke (HR) P Any stroke (SHR) P
SBP, per 10 mmHg 1.20 (1.11–1.29) < 0.001 1.17 (1.09–1.25) < 0.001
DBP, per 10 mmHg 1.21 (1.03–1.42) 0.021 1.19 (1.02–1.37) 0.026
MAP, per 10 mmHg 1.32 (1.16–1.52) < 0.001 1.27 (1.12–1.42) < 0.001
PP, per 10 mmHg 1.19 (1.10–1.30) < 0.001 1.16 (1.07–1.25) < 0.001
Ischemic stroke (HR) P Ischemic stroke (SHR) P
SBP, per 10 mmHg 1.19 (1.09–1.30) < 0.001 1.16 (1.07–1.25) < 0.001
DBP, per 10 mmHg 1.15 (0.95–1.39) 0.148 1.13 (0.94–1.33) 0.170
MAP, per 10 mmHg 1.29 (1.10–1.51) 0.002 1.23 (1.06–1.40) 0.007
PP, per 10 mmHg 1.21 (1.09–1.33) < 0.001 1.17 (1.06–1.27) 0.002
Hemorrhagic stroke (HR) P Hemorrhagic stroke (SHR)
SBP, per 10 mmHg 1.21 (1.05–1.41) 0.010 1.16 (1.02–1.31) 0.023
DBP, per 10 mmHg 1.38 (1.01–1.87) 0.040 1.31 (0.98–1.65) 0.064
MAP, per 10 mmHg 1.42 (1.10–1.85) 0.008 1.32 (1.04–1.59) 0.024
PP, per 10 mmHg 1.16 (0.98–1.38) 0.089 1.13 (0.98–1.27) 0.089
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Association [24], medical treatment of high blood pres-
sure in diabetes should be initiated at blood pressure 
levels of > 140/90  mmHg, and the treatment goal is a 
blood pressure of < 140/90  mmHg. However, a recently 
published guideline by the American Heart Association 
suggested that blood pressure levels in type 1 diabetes 
should be lower, recommending initiation of treatment 
already at blood pressure levels of > 130/80 mmHg, and 
that the blood pressure target should be < 130/80 mmHg 
in individuals with diabetes [22]. The results in our study 
support the new recommendations for blood pres-
sure treatment targets in type 1 diabetes. Furthermore, 
despite the high prevalence of antihypertensive medica-
tion in the participants with stroke blood pressure lev-
els were suboptimal, indicating that a more aggressive 
approach in treating blood pressure in these individuals 
should be considered.
Association of blood pressure variables and stroke
To our surprise, there were no indications of a J-shaped 
phenomenon in our study for any of the studied blood 
pressure variables. The risk of stroke increased linearly 
for all subtypes for SBP, MAP, and PP, while the risk 
increment was non-linear for DBP. For SBP, this is in line 
with the study by Rawshani et al. [7], where the associa-
tion with stroke was also linear. According to Zhao et al. 
[5], the J-shaped association was found mainly in individ-
uals 30–59 years of age, and this association weakened in 
individuals older than 60 years. Even though the partici-
pants in our study were younger than 60 years, mean age 
around 50 years, their blood vessels could resemble those 
of non-diabetic individuals of older age due to the long 
diabetes duration and, thus, alternating blood glucose 
levels. In accordance with this, we have earlier shown 
that the pulse pressure in individuals with type 1 diabe-
tes increases 15 to 20 years earlier than in non-diabetic 
individuals, suggesting early vascular aging in diabetes 
[25]. This can be explained by the fact that hyperglyce-
mia causes endothelial dysfunction, leading to diabetic 
angiopathy and arterial stiffness, and all of these leading 
to hypertension [26–28]. The same changes take place 
in normoglycemic persons during aging [29, 30]. On the 
Fig. 1 Restricted cubic spline models for any stroke and SBP, DBP, MAP, and PP. Risk of any stroke in relation to a systolic blood pressure (SBP), b 
diastolic blood pressure (DBP), c mean arterial pressure (MAP), and d pulse pressure (PP), estimated using restricted cubic spline models with three 
knots. The age‑ and sex‑adjusted hazard ratios (HR) are represented by the solid line and the 95% confidence interval (CI) by the shaded area
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other hand, apart from hypertension, the risk factors 
identified for stroke in type 1 diabetes are different com-
pared to the general population [8, 31, 32]. The etiology 
of stroke is also different. In type 1 diabetes, the major-
ity of strokes are caused by small-vessel disease or stroke 
of unclear etiology, while cardioembolism is less frequent 
in young individuals with type 1 diabetes compared with 
people without diabetes [33]. Carotid stenosis, a marker 
of large-artery atherosclerosis, is also less common, espe-
cially compared to individuals with type 2 diabetes [33]. 
Subclinical atherosclerosis is, however, known to associ-
ate with type 1 diabetes [34], so it might be that some of 
the strokes classified as unclear etiology could be due to 
atherosclerosis. In the present study we were unable to 
assess the etiology of strokes due to variation in and/or 
lack of etiological assessment performed at the different 
hospitals during the different time periods.
Salt intake and stroke
High salt intake, measured as 24-h urinary sodium 
excretion, increases the risk of cardiovascular disease, 
mainly stroke [9, 35]. The same can be seen in individu-
als with chronic kidney disease, for which the risk of 
stroke increases linearly when urinary sodium excretion 
increases [36]. A majority of our participants, 61%, with 
stroke had impaired kidney function, defined as diabetic 
nephropathy. Yet, we did not find any associations with 
urinary sodium and potassium excretion and stroke. 
One possibility for this result could be the low number 
of individuals tested; we only had information on uri-
nary sodium and potassium excretion available for 115 
participants with stroke. Many of these individuals also 
had micro- or macroalbuminuria, which in some part 
affect the urinary excretion. On the other hand, no trends 
towards any associations were seen in the analyses.
Study limitations
One of the weaknesses of this study was that we only 
had an office blood pressure measurement from a single 
time point available, and this could have been measured 
years before the incident stroke. Likewise, 24-h Na and 
24-h K were also measured from a single urine collection. 
Ambulatory 24-h blood pressure or timed blood pres-
sure measurements during a more extended time would 
be the best method to determine the impact of blood 
pressure on the risk of stroke. Unfortunately, in this large 
study population consisting of over 4000 participants, 
this was not feasible. Moreover, already with this single 
office blood pressure, we were able to show an increased 
risk of stroke in these participants, indicating that this 
single blood pressure measurement might be a sensitive 
enough tool to evaluate the risk of stroke years before an 
event.
Another limitation of this study is the number of stroke 
cases, particularly that of hemorrhagic strokes. This 
could affect the impact of sodium and potassium on the 
risk of stroke, as well as the J-shaped vs linear association 
between blood pressure levels and stroke risk. On the 
other hand, in the studies by Cederholm et  al. [37, 38], 
no J-shaped relationships between low SBP and increased 
stroke risk was found even though the number of indi-
viduals was threefold larger in their second study, 13,000 
vs 35,000 participants. Further studies on the potential 
J-shaped association between blood pressure and stroke 
in individuals with type 1 diabetes are required before 
any conclusions can be made.
The number of individuals studied is also one of the 
strengths of this study. Stroke is, fortunately, still a rela-
tively rare complication in this age group. To this date, 
this is the largest study population of individuals with 
type 1 diabetes and stroke ascertained from medical 
files, which allowed us to also perform studies on the 
subgroups of stroke, ischemic and hemorrhagic stroke. 
Another strength in our study is the well-characterized 
population. All of the included strokes were identi-
fied from different sources, the information on strokes 
and their complications were verified from medical 
records, and all the included strokes were confirmed 
and classified with the same methods by expert stroke 
neurologists.
Conclusions
In conclusion, we show that different blood pressure 
variables all independently increase the risk of stroke 
in individuals with type 1 diabetes, and that the risk of 
any stroke, ischemic stroke, and hemorrhagic stroke 
increases linearly already at blood pressure levels lower 
than the current treatment goals. Intensified treatment of 
blood pressure to target levels should be taken into con-
sideration in these individuals in the attempt of reducing 
the risk of future strokes.
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